Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma

Marguerite T. Parisi, Mary K. Greene, Thomas M. Dykes, Thomas V. Moraldo, E. Dayan Sandler, Robert S. Hattner

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Rationale and Objectives: Metaiodobenzylguanidine (MIBG) has been shown to be both sensitive and highly specific for the detection of neuroblastoma. However, controversy surrounds its sensitivity in detecting neuroblastoma when compared with radionuclide (technetium 99m-methylene diphosphonate [99mTc]-MDP) bone scans. Because a diagnostic test ideally should be easy to interpret in addition to being sensitive and specific, this study aims to determine the most efficacious scintigraphic agent for diagnostic use in neuroblastoma. Methods: Twenty patients with neuroblastoma had a total of 26 paired MIBG and 99mTc-MDP bone scans obtained less than 4 weeks apart. Each study was evaluated independently of its counterpart by six separate observers (3 experienced and 3 inexperienced in MIBG scintigraphy) to determine the presence or absence of disease and the tumor burden. Results: Inexperienced observers reported more confidence in their interpretations of 99mTc–MDP bone scans; however, seven false-positive bone scans were reported. Using MIBG, all true-positive and true-negative scans, as well as significantly more sites of both primary and metastatic disease, were identified by all observers. Conclusion: This study suggests that MIBG is the more efficacious agent for the scintigraphic evaluation of neuroblastoma.

Original languageEnglish (US)
Pages (from-to)768-773
Number of pages6
JournalInvestigative Radiology
Volume27
Issue number10
DOIs
StatePublished - Oct 1992

Fingerprint

Neuroblastoma
Technetium Tc 99m Medronate
Bone and Bones
Technetium
Tumor Burden
Routine Diagnostic Tests
Radioisotopes
Radionuclide Imaging

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Parisi, M. T., Greene, M. K., Dykes, T. M., Moraldo, T. V., Sandler, E. D., & Hattner, R. S. (1992). Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Investigative Radiology, 27(10), 768-773. https://doi.org/10.1097/00004424-199210000-00003
Parisi, Marguerite T. ; Greene, Mary K. ; Dykes, Thomas M. ; Moraldo, Thomas V. ; Sandler, E. Dayan ; Hattner, Robert S. / Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. In: Investigative Radiology. 1992 ; Vol. 27, No. 10. pp. 768-773.
@article{94e8038a936747c2a8d23450b147b51c,
title = "Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma",
abstract = "Rationale and Objectives: Metaiodobenzylguanidine (MIBG) has been shown to be both sensitive and highly specific for the detection of neuroblastoma. However, controversy surrounds its sensitivity in detecting neuroblastoma when compared with radionuclide (technetium 99m-methylene diphosphonate [99mTc]-MDP) bone scans. Because a diagnostic test ideally should be easy to interpret in addition to being sensitive and specific, this study aims to determine the most efficacious scintigraphic agent for diagnostic use in neuroblastoma. Methods: Twenty patients with neuroblastoma had a total of 26 paired MIBG and 99mTc-MDP bone scans obtained less than 4 weeks apart. Each study was evaluated independently of its counterpart by six separate observers (3 experienced and 3 inexperienced in MIBG scintigraphy) to determine the presence or absence of disease and the tumor burden. Results: Inexperienced observers reported more confidence in their interpretations of 99mTc–MDP bone scans; however, seven false-positive bone scans were reported. Using MIBG, all true-positive and true-negative scans, as well as significantly more sites of both primary and metastatic disease, were identified by all observers. Conclusion: This study suggests that MIBG is the more efficacious agent for the scintigraphic evaluation of neuroblastoma.",
author = "Parisi, {Marguerite T.} and Greene, {Mary K.} and Dykes, {Thomas M.} and Moraldo, {Thomas V.} and Sandler, {E. Dayan} and Hattner, {Robert S.}",
year = "1992",
month = "10",
doi = "10.1097/00004424-199210000-00003",
language = "English (US)",
volume = "27",
pages = "768--773",
journal = "Investigative Radiology",
issn = "0020-9996",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

Parisi, MT, Greene, MK, Dykes, TM, Moraldo, TV, Sandler, ED & Hattner, RS 1992, 'Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma', Investigative Radiology, vol. 27, no. 10, pp. 768-773. https://doi.org/10.1097/00004424-199210000-00003

Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. / Parisi, Marguerite T.; Greene, Mary K.; Dykes, Thomas M.; Moraldo, Thomas V.; Sandler, E. Dayan; Hattner, Robert S.

In: Investigative Radiology, Vol. 27, No. 10, 10.1992, p. 768-773.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma

AU - Parisi, Marguerite T.

AU - Greene, Mary K.

AU - Dykes, Thomas M.

AU - Moraldo, Thomas V.

AU - Sandler, E. Dayan

AU - Hattner, Robert S.

PY - 1992/10

Y1 - 1992/10

N2 - Rationale and Objectives: Metaiodobenzylguanidine (MIBG) has been shown to be both sensitive and highly specific for the detection of neuroblastoma. However, controversy surrounds its sensitivity in detecting neuroblastoma when compared with radionuclide (technetium 99m-methylene diphosphonate [99mTc]-MDP) bone scans. Because a diagnostic test ideally should be easy to interpret in addition to being sensitive and specific, this study aims to determine the most efficacious scintigraphic agent for diagnostic use in neuroblastoma. Methods: Twenty patients with neuroblastoma had a total of 26 paired MIBG and 99mTc-MDP bone scans obtained less than 4 weeks apart. Each study was evaluated independently of its counterpart by six separate observers (3 experienced and 3 inexperienced in MIBG scintigraphy) to determine the presence or absence of disease and the tumor burden. Results: Inexperienced observers reported more confidence in their interpretations of 99mTc–MDP bone scans; however, seven false-positive bone scans were reported. Using MIBG, all true-positive and true-negative scans, as well as significantly more sites of both primary and metastatic disease, were identified by all observers. Conclusion: This study suggests that MIBG is the more efficacious agent for the scintigraphic evaluation of neuroblastoma.

AB - Rationale and Objectives: Metaiodobenzylguanidine (MIBG) has been shown to be both sensitive and highly specific for the detection of neuroblastoma. However, controversy surrounds its sensitivity in detecting neuroblastoma when compared with radionuclide (technetium 99m-methylene diphosphonate [99mTc]-MDP) bone scans. Because a diagnostic test ideally should be easy to interpret in addition to being sensitive and specific, this study aims to determine the most efficacious scintigraphic agent for diagnostic use in neuroblastoma. Methods: Twenty patients with neuroblastoma had a total of 26 paired MIBG and 99mTc-MDP bone scans obtained less than 4 weeks apart. Each study was evaluated independently of its counterpart by six separate observers (3 experienced and 3 inexperienced in MIBG scintigraphy) to determine the presence or absence of disease and the tumor burden. Results: Inexperienced observers reported more confidence in their interpretations of 99mTc–MDP bone scans; however, seven false-positive bone scans were reported. Using MIBG, all true-positive and true-negative scans, as well as significantly more sites of both primary and metastatic disease, were identified by all observers. Conclusion: This study suggests that MIBG is the more efficacious agent for the scintigraphic evaluation of neuroblastoma.

UR - http://www.scopus.com/inward/record.url?scp=0026709403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026709403&partnerID=8YFLogxK

U2 - 10.1097/00004424-199210000-00003

DO - 10.1097/00004424-199210000-00003

M3 - Article

C2 - 1399431

AN - SCOPUS:0026709403

VL - 27

SP - 768

EP - 773

JO - Investigative Radiology

JF - Investigative Radiology

SN - 0020-9996

IS - 10

ER -